Baseline variables predictive of conversion from possible to clinically definite MS: ETOMS results

被引：0
|
作者：
Martinelli-Boneschi, F
Hartung, HP
Sorensen, PS
Edan, G
Fernandez, O
Durelli, L
Roveris, M
Seeldrayers, P
Barkhof, F
Filippi, M
Hommes, O
Comi, G
机构：
来源：
NEUROLOGY | 2002年 / 58卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A504 / A504
页数：1
相关论文
共 50 条
  • [1] Predictive factors of conversion of clinically isolated syndrome to clinically definite multiple sclerosis
    Kolcava, J.
    Vlckova, E.
    Pelisek, O.
    Kocica, J.
    Krkoska, P.
    Bednarik, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 640 - 641
  • [2] Diagnostic MRI criteria: Prediction of conversion to clinically definite MS
    Barkhof, F
    Filippi, M
    Comi, G
    NEUROLOGY, 2002, 58 (07) : A157 - A157
  • [3] Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS
    Zivadinov, Robert
    Dwyer, Michael G.
    Carl, Ellen
    Poole, Elizabeth M.
    Cavalier, Steve
    Briassouli, Paraskevi
    Bergsland, Niels
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
  • [4] MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group
    O'Connor, P
    Fleming, P
    Gray, T
    Jacobs, L
    Miller, C
    Munschauer, F
    Kinkel, RP
    Bolibrush, D
    Cohen, J
    Freedman, M
    Webb, U
    Rabinowicz, H
    Metz, LM
    Patry, D
    Yeung, M
    Peters, S
    Hashimoto, S
    Morrison, W
    Oger, J
    Panitch, H
    Costello, K
    Bever, C
    Stuart, W
    Court, D
    Stuart, D
    Tornatore, C
    Bartlett, D
    Richert, J
    Duquette, P
    Dubois, R
    Bernier, G
    Scott, T
    Pappert, L
    Brillman, J
    Felton, W
    Anderson, T
    Astruc, J
    Rose, J
    Kline, J
    Burns, J
    Murray, T
    Weldon, P
    Bhan, V
    Maxner, CE
    Wall, M
    Vining, L
    Grabowski, T
    Apatoff, B
    Orapello, C
    Friedman, J
    NEUROLOGY, 2002, 59 (07) : 998 - 1005
  • [5] Oral Cladribine Delays Time to Conversion to Clinically Definite MS in Patients with a First Demyelinating Event: Top Line Results from the Phase III ORACLE MS Study
    Leist, Thomas
    Comi, Giancarlo
    Cree, Bruce
    Coyle, Patricia
    Freedman, Mark
    Hartung, Hans
    Vermersch, Patrick
    Orejudos, Amelia
    Lachenal, Nathalie
    Scaramozza, Matthew
    NEUROLOGY, 2013, 80
  • [6] Combined omics analysis of cerebrospinal fluid is able to predict conversion from clinically isolated syndrome to clinically definite MS within 4 years
    Probert, F.
    Yeo, T.
    Sealey, M.
    Palace, J.
    Leppert, D.
    Kuhle, J.
    Anthony, D. C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 277 - 278
  • [7] Treatment with glatiramer acetate delays conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome suggestive of MS
    Comi, G.
    Filippi, M.
    JOURNAL OF NEUROLOGY, 2008, 255 : 10 - 10
  • [8] Slowing of cortical grey matter atrophy with teriflunomide is associated with delayed conversion to clinically definite MS
    Zivadinov, R.
    Dwyer, M. G.
    Carl, E.
    Thangavelu, K.
    Cavalier, S.
    Bergsland, N.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 321 - 322
  • [9] Slowing of whole brain volume loss with teriflunomide is associated with delayed conversion to clinically definite MS
    Zivadinov, R.
    Dwyer, M.
    Carl, E.
    Poole, E.
    Cavalier, S.
    Bergsland, N.
    Roesch, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 872 - 872
  • [10] PREDICTIVE VALUE OF C-REACTIVE PROTEIN AND CLINICALLY RELEVANT BASELINE VARIABLES IN SARCOIDOSIS
    McDonnell, Melissa J.
    Saleem, Mohammed I.
    Wall, Deidre
    Gilmartin, J. J.
    Rutherford, R. M.
    O'Regan, Anthony
    SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2016, 33 (04) : 331 - 340
12345